South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the domestic drugmaker said on Wednesday.
As part of the deal, Cadila will transfer the DNA vaccine technology to Enzychem, which will make and sell the vaccine, ZyCoV-D, within its territory under the Cadila trademark. Cadila will get license fees and royalty payments, the company said in a filing to stock exchanges.
"(The DNA) technology allows vaccines to be produced at affordable costs in record times, and DNA vaccines are considerably stable," said Ki Young Sohn, chairman of Enzychem Lifesciences.
"ZyCoV-D is administered without needles and can be deployed more readily, especially in resource-poor populations."
Cadila's vaccine, which is administered in three doses, was approved by the country's drug regulator in August for emergency use in adults and children aged 12 years and above, though it has yet to be rolled out as part of the county's vaccination drive.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Covid Vaccinated Pregnant Women At Lower Risk Of Caesarean Births: Study Fact Check: Can Covaxin Lead To Death After 2 Years Of Vaccination? Woman On Scooter With 2 Kids Punched, Left Bleeding In Pune Road Rage Case After Retest, Haryana NEET Centre With Most Top Scorers Gave This Result... 500 Para Commandos To Hunt Pakistani Terrorists In Jammu After Attacks Goods Train Derails in UP's Amroha, 15 Trains Cancelled Or Diverted BJP Will Protect Tribal Lands If Voted To Power: Amit Shah In Jharkhand 7 Arrested In Goa For Cheating US Citizens Through Fake Call Centre Track Latest News Live on NDTV.com and get news updates from India and around the world.